6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study.
Identifieur interne : 004158 ( PubMed/Checkpoint ); précédent : 004157; suivant : 0041596MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study.
Auteurs : Smita Bhatia [États-Unis] ; Wendy Landier [États-Unis] ; Lindsey Hageman [États-Unis] ; Heeyoung Kim [États-Unis] ; Yanjun Chen [États-Unis] ; Kristine R. Crews [États-Unis] ; William E. Evans [États-Unis] ; Bruce Bostrom [États-Unis] ; Jacqueline Casillas [États-Unis] ; David S. Dickens [États-Unis] ; Kelly W. Maloney [États-Unis] ; Joseph P. Neglia [États-Unis] ; Yaddanapudi Ravindranath ; A Kim Ritchey [États-Unis] ; F Lennie Wong [États-Unis] ; Mary V. Relling [États-Unis]Source :
- Blood [ 1528-0020 ] ; 2014.
Descripteurs français
- KwdFr :
- Administration par voie orale, Adolescent, Analyse de régression, Analyse multivariée, Démographie, Enfant, Enfant d'âge préscolaire, Femelle, Humains, Jeune adulte, Leucémie-lymphome lymphoblastique à précurseurs B et T (ethnologie), Leucémie-lymphome lymphoblastique à précurseurs B et T (traitement médicamenteux), Mercaptopurine (administration et posologie), Mercaptopurine (usage thérapeutique), Mâle, Nourrisson, Observance du traitement médicamenteux (ethnologie), Populations d'origine continentale (ethnologie), Récidive, Études de cohortes.
- MESH :
- administration et posologie : Mercaptopurine.
- ethnologie : Leucémie-lymphome lymphoblastique à précurseurs B et T, Observance du traitement médicamenteux, Populations d'origine continentale.
- traitement médicamenteux : Leucémie-lymphome lymphoblastique à précurseurs B et T.
- usage thérapeutique : Mercaptopurine.
- Administration par voie orale, Adolescent, Analyse de régression, Analyse multivariée, Démographie, Enfant, Enfant d'âge préscolaire, Femelle, Humains, Jeune adulte, Mâle, Nourrisson, Récidive, Études de cohortes.
English descriptors
- KwdEn :
- 6-Mercaptopurine (administration & dosage), 6-Mercaptopurine (therapeutic use), Administration, Oral, Adolescent, Child, Child, Preschool, Cohort Studies, Continental Population Groups (ethnology), Demography, Female, Humans, Infant, Male, Medication Adherence (ethnology), Multivariate Analysis, Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy), Precursor Cell Lymphoblastic Leukemia-Lymphoma (ethnology), Recurrence, Regression Analysis, Young Adult.
- MESH :
- chemical , administration & dosage : 6-Mercaptopurine.
- chemical , therapeutic use : 6-Mercaptopurine.
- drug therapy : Precursor Cell Lymphoblastic Leukemia-Lymphoma.
- ethnology : Continental Population Groups, Medication Adherence, Precursor Cell Lymphoblastic Leukemia-Lymphoma.
- Administration, Oral, Adolescent, Child, Child, Preschool, Cohort Studies, Demography, Female, Humans, Infant, Male, Multivariate Analysis, Recurrence, Regression Analysis, Young Adult.
Abstract
Durable remissions in children with acute lymphoblastic leukemia (ALL) require a 2-year maintenance phase that includes daily oral 6-mercaptopurine (6MP). Adherence to oral 6MP among Asian-American and African-American children with ALL is unknown. We enrolled 298 children with ALL (71 Asian Americans, 68 African Americans, and 159 non-Hispanic whites) receiving oral 6MP for the maintenance phase. Adherence was measured electronically for 39 803 person-days. Adherence declined from 95.0% (month 1) to 91.8% (month 5, P < .0001). Adherence rates were significantly (P < .0001) lower in Asian Americans (90.0% ± 4.9%) and African Americans (87.1% ± 4.4%), as compared with non-Hispanic whites (95.2% ± 1.3%). Race-specific sociodemographic characteristics helped explain poor adherence (African Americans: low maternal education [less than a college degree: 78.9%, vs at least college degree: 94.6%; P < .0001]; Asian Americans: low-income households [<$50 000: 84.5%, vs ≥$50 000: 96.7%; P = .04]; households without mothers as full-time caregivers [85.6%] vs households with mothers as full-time caregivers [97.2%; P = .05]). Adherence rate below 90% was associated with increased relapse risk (hazard ratio, 3.9; P = .01). Using an adherence rate <90% to define nonadherence, 20.5% of the participants were nonadherers. We identify race-specific determinants of adherence, and define a clinically relevant level of adherence needed to minimize relapse risk in a multiracial cohort of children with ALL. This trial was registered at www.clinicaltrials.gov as #NCT00268528.
DOI: 10.1182/blood-2014-01-552166
PubMed: 24829202
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:24829202Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study.</title><author><name sortKey="Bhatia, Smita" sort="Bhatia, Smita" uniqKey="Bhatia S" first="Smita" last="Bhatia">Smita Bhatia</name><affiliation wicri:level="2"><nlm:affiliation>Department of Population Sciences, City of Hope, Duarte, CA;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Population Sciences, City of Hope, Duarte</wicri:cityArea></affiliation></author><author><name sortKey="Landier, Wendy" sort="Landier, Wendy" uniqKey="Landier W" first="Wendy" last="Landier">Wendy Landier</name><affiliation wicri:level="2"><nlm:affiliation>Department of Population Sciences, City of Hope, Duarte, CA;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Population Sciences, City of Hope, Duarte</wicri:cityArea></affiliation></author><author><name sortKey="Hageman, Lindsey" sort="Hageman, Lindsey" uniqKey="Hageman L" first="Lindsey" last="Hageman">Lindsey Hageman</name><affiliation wicri:level="2"><nlm:affiliation>Department of Population Sciences, City of Hope, Duarte, CA;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Population Sciences, City of Hope, Duarte</wicri:cityArea></affiliation></author><author><name sortKey="Kim, Heeyoung" sort="Kim, Heeyoung" uniqKey="Kim H" first="Heeyoung" last="Kim">Heeyoung Kim</name><affiliation wicri:level="2"><nlm:affiliation>Department of Population Sciences, City of Hope, Duarte, CA;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Population Sciences, City of Hope, Duarte</wicri:cityArea></affiliation></author><author><name sortKey="Chen, Yanjun" sort="Chen, Yanjun" uniqKey="Chen Y" first="Yanjun" last="Chen">Yanjun Chen</name><affiliation wicri:level="2"><nlm:affiliation>Department of Population Sciences, City of Hope, Duarte, CA;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Population Sciences, City of Hope, Duarte</wicri:cityArea></affiliation></author><author><name sortKey="Crews, Kristine R" sort="Crews, Kristine R" uniqKey="Crews K" first="Kristine R" last="Crews">Kristine R. Crews</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis</wicri:cityArea></affiliation></author><author><name sortKey="Evans, William E" sort="Evans, William E" uniqKey="Evans W" first="William E" last="Evans">William E. Evans</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis</wicri:cityArea></affiliation></author><author><name sortKey="Bostrom, Bruce" sort="Bostrom, Bruce" uniqKey="Bostrom B" first="Bruce" last="Bostrom">Bruce Bostrom</name><affiliation wicri:level="2"><nlm:affiliation>Department of Hematology/Oncology, Children's Hospitals and Clinics of Minnesota, Minneapolis, MN;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Minnesota</region></placeName><wicri:cityArea>Department of Hematology/Oncology, Children's Hospitals and Clinics of Minnesota, Minneapolis</wicri:cityArea></affiliation></author><author><name sortKey="Casillas, Jacqueline" sort="Casillas, Jacqueline" uniqKey="Casillas J" first="Jacqueline" last="Casillas">Jacqueline Casillas</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pediatrics and Division of Hematology/Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Pediatrics and Division of Hematology/Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles</wicri:cityArea></affiliation></author><author><name sortKey="Dickens, David S" sort="Dickens, David S" uniqKey="Dickens D" first="David S" last="Dickens">David S. Dickens</name><affiliation wicri:level="2"><nlm:affiliation>Division of Pediatric Hematology/Oncology, Helen DeVos Children's Hospital at Spectrum Health/Spectrum Health at Butterworth Campus, Grand Rapids, MI;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Division of Pediatric Hematology/Oncology, Helen DeVos Children's Hospital at Spectrum Health/Spectrum Health at Butterworth Campus, Grand Rapids</wicri:cityArea></affiliation></author><author><name sortKey="Maloney, Kelly W" sort="Maloney, Kelly W" uniqKey="Maloney K" first="Kelly W" last="Maloney">Kelly W. Maloney</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Colorado</region></placeName><wicri:cityArea>Department of Pediatrics, University of Colorado School of Medicine, Aurora</wicri:cityArea></affiliation></author><author><name sortKey="Neglia, Joseph P" sort="Neglia, Joseph P" uniqKey="Neglia J" first="Joseph P" last="Neglia">Joseph P. Neglia</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Minnesota Medical School, Minneapolis, MN;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Minnesota</region></placeName><wicri:cityArea>Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Minnesota Medical School, Minneapolis</wicri:cityArea></affiliation></author><author><name sortKey="Ravindranath, Yaddanapudi" sort="Ravindranath, Yaddanapudi" uniqKey="Ravindranath Y" first="Yaddanapudi" last="Ravindranath">Yaddanapudi Ravindranath</name><affiliation><nlm:affiliation>Division of Hematology/Oncology, Children's Hospital of Michigan, Detroit, MI; and.</nlm:affiliation><wicri:noCountry code="subField">MI; and</wicri:noCountry></affiliation></author><author><name sortKey="Ritchey, A Kim" sort="Ritchey, A Kim" uniqKey="Ritchey A" first="A Kim" last="Ritchey">A Kim Ritchey</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pediatrics, Division of Hematology/Oncology, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh, PA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Department of Pediatrics, Division of Hematology/Oncology, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh</wicri:cityArea></affiliation></author><author><name sortKey="Wong, F Lennie" sort="Wong, F Lennie" uniqKey="Wong F" first="F Lennie" last="Wong">F Lennie Wong</name><affiliation wicri:level="2"><nlm:affiliation>Department of Population Sciences, City of Hope, Duarte, CA;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Population Sciences, City of Hope, Duarte</wicri:cityArea></affiliation></author><author><name sortKey="Relling, Mary V" sort="Relling, Mary V" uniqKey="Relling M" first="Mary V" last="Relling">Mary V. Relling</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24829202</idno><idno type="pmid">24829202</idno><idno type="doi">10.1182/blood-2014-01-552166</idno><idno type="wicri:Area/PubMed/Corpus">001740</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001740</idno><idno type="wicri:Area/PubMed/Curation">001733</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001733</idno><idno type="wicri:Area/PubMed/Checkpoint">001733</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001733</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study.</title><author><name sortKey="Bhatia, Smita" sort="Bhatia, Smita" uniqKey="Bhatia S" first="Smita" last="Bhatia">Smita Bhatia</name><affiliation wicri:level="2"><nlm:affiliation>Department of Population Sciences, City of Hope, Duarte, CA;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Population Sciences, City of Hope, Duarte</wicri:cityArea></affiliation></author><author><name sortKey="Landier, Wendy" sort="Landier, Wendy" uniqKey="Landier W" first="Wendy" last="Landier">Wendy Landier</name><affiliation wicri:level="2"><nlm:affiliation>Department of Population Sciences, City of Hope, Duarte, CA;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Population Sciences, City of Hope, Duarte</wicri:cityArea></affiliation></author><author><name sortKey="Hageman, Lindsey" sort="Hageman, Lindsey" uniqKey="Hageman L" first="Lindsey" last="Hageman">Lindsey Hageman</name><affiliation wicri:level="2"><nlm:affiliation>Department of Population Sciences, City of Hope, Duarte, CA;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Population Sciences, City of Hope, Duarte</wicri:cityArea></affiliation></author><author><name sortKey="Kim, Heeyoung" sort="Kim, Heeyoung" uniqKey="Kim H" first="Heeyoung" last="Kim">Heeyoung Kim</name><affiliation wicri:level="2"><nlm:affiliation>Department of Population Sciences, City of Hope, Duarte, CA;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Population Sciences, City of Hope, Duarte</wicri:cityArea></affiliation></author><author><name sortKey="Chen, Yanjun" sort="Chen, Yanjun" uniqKey="Chen Y" first="Yanjun" last="Chen">Yanjun Chen</name><affiliation wicri:level="2"><nlm:affiliation>Department of Population Sciences, City of Hope, Duarte, CA;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Population Sciences, City of Hope, Duarte</wicri:cityArea></affiliation></author><author><name sortKey="Crews, Kristine R" sort="Crews, Kristine R" uniqKey="Crews K" first="Kristine R" last="Crews">Kristine R. Crews</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis</wicri:cityArea></affiliation></author><author><name sortKey="Evans, William E" sort="Evans, William E" uniqKey="Evans W" first="William E" last="Evans">William E. Evans</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis</wicri:cityArea></affiliation></author><author><name sortKey="Bostrom, Bruce" sort="Bostrom, Bruce" uniqKey="Bostrom B" first="Bruce" last="Bostrom">Bruce Bostrom</name><affiliation wicri:level="2"><nlm:affiliation>Department of Hematology/Oncology, Children's Hospitals and Clinics of Minnesota, Minneapolis, MN;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Minnesota</region></placeName><wicri:cityArea>Department of Hematology/Oncology, Children's Hospitals and Clinics of Minnesota, Minneapolis</wicri:cityArea></affiliation></author><author><name sortKey="Casillas, Jacqueline" sort="Casillas, Jacqueline" uniqKey="Casillas J" first="Jacqueline" last="Casillas">Jacqueline Casillas</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pediatrics and Division of Hematology/Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Pediatrics and Division of Hematology/Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles</wicri:cityArea></affiliation></author><author><name sortKey="Dickens, David S" sort="Dickens, David S" uniqKey="Dickens D" first="David S" last="Dickens">David S. Dickens</name><affiliation wicri:level="2"><nlm:affiliation>Division of Pediatric Hematology/Oncology, Helen DeVos Children's Hospital at Spectrum Health/Spectrum Health at Butterworth Campus, Grand Rapids, MI;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Division of Pediatric Hematology/Oncology, Helen DeVos Children's Hospital at Spectrum Health/Spectrum Health at Butterworth Campus, Grand Rapids</wicri:cityArea></affiliation></author><author><name sortKey="Maloney, Kelly W" sort="Maloney, Kelly W" uniqKey="Maloney K" first="Kelly W" last="Maloney">Kelly W. Maloney</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Colorado</region></placeName><wicri:cityArea>Department of Pediatrics, University of Colorado School of Medicine, Aurora</wicri:cityArea></affiliation></author><author><name sortKey="Neglia, Joseph P" sort="Neglia, Joseph P" uniqKey="Neglia J" first="Joseph P" last="Neglia">Joseph P. Neglia</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Minnesota Medical School, Minneapolis, MN;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Minnesota</region></placeName><wicri:cityArea>Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Minnesota Medical School, Minneapolis</wicri:cityArea></affiliation></author><author><name sortKey="Ravindranath, Yaddanapudi" sort="Ravindranath, Yaddanapudi" uniqKey="Ravindranath Y" first="Yaddanapudi" last="Ravindranath">Yaddanapudi Ravindranath</name><affiliation><nlm:affiliation>Division of Hematology/Oncology, Children's Hospital of Michigan, Detroit, MI; and.</nlm:affiliation><wicri:noCountry code="subField">MI; and</wicri:noCountry></affiliation></author><author><name sortKey="Ritchey, A Kim" sort="Ritchey, A Kim" uniqKey="Ritchey A" first="A Kim" last="Ritchey">A Kim Ritchey</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pediatrics, Division of Hematology/Oncology, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh, PA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Department of Pediatrics, Division of Hematology/Oncology, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh</wicri:cityArea></affiliation></author><author><name sortKey="Wong, F Lennie" sort="Wong, F Lennie" uniqKey="Wong F" first="F Lennie" last="Wong">F Lennie Wong</name><affiliation wicri:level="2"><nlm:affiliation>Department of Population Sciences, City of Hope, Duarte, CA;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Population Sciences, City of Hope, Duarte</wicri:cityArea></affiliation></author><author><name sortKey="Relling, Mary V" sort="Relling, Mary V" uniqKey="Relling M" first="Mary V" last="Relling">Mary V. Relling</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis</wicri:cityArea></affiliation></author></analytic><series><title level="j">Blood</title><idno type="eISSN">1528-0020</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>6-Mercaptopurine (administration & dosage)</term><term>6-Mercaptopurine (therapeutic use)</term><term>Administration, Oral</term><term>Adolescent</term><term>Child</term><term>Child, Preschool</term><term>Cohort Studies</term><term>Continental Population Groups (ethnology)</term><term>Demography</term><term>Female</term><term>Humans</term><term>Infant</term><term>Male</term><term>Medication Adherence (ethnology)</term><term>Multivariate Analysis</term><term>Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy)</term><term>Precursor Cell Lymphoblastic Leukemia-Lymphoma (ethnology)</term><term>Recurrence</term><term>Regression Analysis</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie orale</term><term>Adolescent</term><term>Analyse de régression</term><term>Analyse multivariée</term><term>Démographie</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Leucémie-lymphome lymphoblastique à précurseurs B et T (ethnologie)</term><term>Leucémie-lymphome lymphoblastique à précurseurs B et T (traitement médicamenteux)</term><term>Mercaptopurine (administration et posologie)</term><term>Mercaptopurine (usage thérapeutique)</term><term>Mâle</term><term>Nourrisson</term><term>Observance du traitement médicamenteux (ethnologie)</term><term>Populations d'origine continentale (ethnologie)</term><term>Récidive</term><term>Études de cohortes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>6-Mercaptopurine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>6-Mercaptopurine</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Mercaptopurine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</term></keywords><keywords scheme="MESH" qualifier="ethnologie" xml:lang="fr"><term>Leucémie-lymphome lymphoblastique à précurseurs B et T</term><term>Observance du traitement médicamenteux</term><term>Populations d'origine continentale</term></keywords><keywords scheme="MESH" qualifier="ethnology" xml:lang="en"><term>Continental Population Groups</term><term>Medication Adherence</term><term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Leucémie-lymphome lymphoblastique à précurseurs B et T</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Mercaptopurine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Adolescent</term><term>Child</term><term>Child, Preschool</term><term>Cohort Studies</term><term>Demography</term><term>Female</term><term>Humans</term><term>Infant</term><term>Male</term><term>Multivariate Analysis</term><term>Recurrence</term><term>Regression Analysis</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie orale</term><term>Adolescent</term><term>Analyse de régression</term><term>Analyse multivariée</term><term>Démographie</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Nourrisson</term><term>Récidive</term><term>Études de cohortes</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Durable remissions in children with acute lymphoblastic leukemia (ALL) require a 2-year maintenance phase that includes daily oral 6-mercaptopurine (6MP). Adherence to oral 6MP among Asian-American and African-American children with ALL is unknown. We enrolled 298 children with ALL (71 Asian Americans, 68 African Americans, and 159 non-Hispanic whites) receiving oral 6MP for the maintenance phase. Adherence was measured electronically for 39 803 person-days. Adherence declined from 95.0% (month 1) to 91.8% (month 5, P < .0001). Adherence rates were significantly (P < .0001) lower in Asian Americans (90.0% ± 4.9%) and African Americans (87.1% ± 4.4%), as compared with non-Hispanic whites (95.2% ± 1.3%). Race-specific sociodemographic characteristics helped explain poor adherence (African Americans: low maternal education [less than a college degree: 78.9%, vs at least college degree: 94.6%; P < .0001]; Asian Americans: low-income households [<$50 000: 84.5%, vs ≥$50 000: 96.7%; P = .04]; households without mothers as full-time caregivers [85.6%] vs households with mothers as full-time caregivers [97.2%; P = .05]). Adherence rate below 90% was associated with increased relapse risk (hazard ratio, 3.9; P = .01). Using an adherence rate <90% to define nonadherence, 20.5% of the participants were nonadherers. We identify race-specific determinants of adherence, and define a clinically relevant level of adherence needed to minimize relapse risk in a multiracial cohort of children with ALL. This trial was registered at www.clinicaltrials.gov as #NCT00268528.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24829202</PMID><DateCreated><Year>2014</Year><Month>10</Month><Day>10</Day></DateCreated><DateCompleted><Year>2015</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1528-0020</ISSN><JournalIssue CitedMedium="Internet"><Volume>124</Volume><Issue>15</Issue><PubDate><Year>2014</Year><Month>Oct</Month><Day>09</Day></PubDate></JournalIssue><Title>Blood</Title><ISOAbbreviation>Blood</ISOAbbreviation></Journal><ArticleTitle>6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study.</ArticleTitle><Pagination><MedlinePgn>2345-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1182/blood-2014-01-552166</ELocationID><Abstract><AbstractText>Durable remissions in children with acute lymphoblastic leukemia (ALL) require a 2-year maintenance phase that includes daily oral 6-mercaptopurine (6MP). Adherence to oral 6MP among Asian-American and African-American children with ALL is unknown. We enrolled 298 children with ALL (71 Asian Americans, 68 African Americans, and 159 non-Hispanic whites) receiving oral 6MP for the maintenance phase. Adherence was measured electronically for 39 803 person-days. Adherence declined from 95.0% (month 1) to 91.8% (month 5, P < .0001). Adherence rates were significantly (P < .0001) lower in Asian Americans (90.0% ± 4.9%) and African Americans (87.1% ± 4.4%), as compared with non-Hispanic whites (95.2% ± 1.3%). Race-specific sociodemographic characteristics helped explain poor adherence (African Americans: low maternal education [less than a college degree: 78.9%, vs at least college degree: 94.6%; P < .0001]; Asian Americans: low-income households [<$50 000: 84.5%, vs ≥$50 000: 96.7%; P = .04]; households without mothers as full-time caregivers [85.6%] vs households with mothers as full-time caregivers [97.2%; P = .05]). Adherence rate below 90% was associated with increased relapse risk (hazard ratio, 3.9; P = .01). Using an adherence rate <90% to define nonadherence, 20.5% of the participants were nonadherers. We identify race-specific determinants of adherence, and define a clinically relevant level of adherence needed to minimize relapse risk in a multiracial cohort of children with ALL. This trial was registered at www.clinicaltrials.gov as #NCT00268528.</AbstractText><CopyrightInformation>© 2014 by The American Society of Hematology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bhatia</LastName><ForeName>Smita</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Population Sciences, City of Hope, Duarte, CA;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landier</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Population Sciences, City of Hope, Duarte, CA;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hageman</LastName><ForeName>Lindsey</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Population Sciences, City of Hope, Duarte, CA;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Heeyoung</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Population Sciences, City of Hope, Duarte, CA;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yanjun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Population Sciences, City of Hope, Duarte, CA;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crews</LastName><ForeName>Kristine R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>William E</ForeName><Initials>WE</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bostrom</LastName><ForeName>Bruce</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Hematology/Oncology, Children's Hospitals and Clinics of Minnesota, Minneapolis, MN;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casillas</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Division of Hematology/Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickens</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Division of Pediatric Hematology/Oncology, Helen DeVos Children's Hospital at Spectrum Health/Spectrum Health at Butterworth Campus, Grand Rapids, MI;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maloney</LastName><ForeName>Kelly W</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neglia</LastName><ForeName>Joseph P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Minnesota Medical School, Minneapolis, MN;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravindranath</LastName><ForeName>Yaddanapudi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Children's Hospital of Michigan, Detroit, MI; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ritchey</LastName><ForeName>A Kim</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Division of Hematology/Oncology, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>F Lennie</ForeName><Initials>FL</Initials><AffiliationInfo><Affiliation>Department of Population Sciences, City of Hope, Duarte, CA;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Relling</LastName><ForeName>Mary V</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN;</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00268528</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R37 CA36401</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>CA 156449</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA096670</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 CA036401</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U10 CA095861</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC4 CA156449</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UG1 CA189955</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA021765</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR000043</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U10 CA098543</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA033572</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM 92666</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01-RR00043</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>CA 21765</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U10 CA180886</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 GM092666</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>05</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Blood</MedlineTA><NlmUniqueID>7603509</NlmUniqueID><ISSNLinking>0006-4971</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>E7WED276I5</RegistryNumber><NameOfSubstance UI="D015122">6-Mercaptopurine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Stat Methods Med Res. 2001 Jun;10(3):195-216</RefSource><PMID Version="1">11446148</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood Rev. 2004 Jun;18(2):115-36</RefSource><PMID Version="1">15010150</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Pediatr Adolesc Med. 2003 Mar;157(3):249-55</RefSource><PMID Version="1">12622674</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2006 Jan 12;354(2):166-78</RefSource><PMID Version="1">16407512</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Care. 2006 Aug;18(6):589-96</RefSource><PMID Version="1">16831787</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2008 Jan 15;112(2):416-32</RefSource><PMID Version="1">18074355</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Health Serv Res. 2009;9:24</RefSource><PMID Version="1">19200387</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Ther. 2009 Oct;31(10):2178-88; discussion 2150-1</RefSource><PMID Version="1">19922889</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Behav. 2011 Oct;15(7):1429-36</RefSource><PMID Version="1">20632081</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Health Commun. 2011;16 Suppl 3:268-78</RefSource><PMID Version="1">21951257</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Patient Care STDS. 2011 Dec;25(12):735-41</RefSource><PMID Version="1">21495860</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2003 Oct 15;290(15):2008-14</RefSource><PMID Version="1">14559954</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2002 Sep 15;100(6):1957-64</RefSource><PMID Version="1">12200352</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 1979 Jan;43(1):169-73</RefSource><PMID Version="1">761160</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 1986 Sep 1;58(5):1179-84</RefSource><PMID Version="1">3731045</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>S Afr Med J. 1989 May 20;75(10):481-4</RefSource><PMID Version="1">2727828</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 1989 Dec;7(12):1816-23</RefSource><PMID Version="1">2585022</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1990 Jul 5;323(1):17-21</RefSource><PMID Version="1">2355954</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1990 Jul 28;336(8709):225-9</RefSource><PMID Version="1">1973780</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMJ. 1993 May 8;306(6887):1239-40</RefSource><PMID Version="1">8499854</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 1995 Feb;13(2):345-51</RefSource><PMID Version="1">7531219</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 1995 Oct;72(4):1004-6</RefSource><PMID Version="1">7547211</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 1996 Jan;14(1):18-24</RefSource><PMID Version="1">8558195</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Intern Med. 1997 Apr 15;126(8):608-14</RefSource><PMID Version="1">9103127</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Pharmacokinet. 1997 May;32(5):345-56</RefSource><PMID Version="1">9160169</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Med Pediatr Oncol. 1998 Feb;30(2):85-90</RefSource><PMID Version="1">9403015</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 1999 May 1;93(9):2817-23</RefSource><PMID Version="1">10216075</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Chromatogr B Biomed Sci Appl. 1999 Sep 24;732(2):459-68</RefSource><PMID Version="1">10517368</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2005 Aug 4;353(5):487-97</RefSource><PMID Version="1">16079372</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2000 Feb;18(4):813-23</RefSource><PMID Version="1">10673523</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2012 Apr 12;119(15):3512-22</RefSource><PMID Version="1">22368272</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pediatrics. 2012 Jun;129(6):e1404-10</RefSource><PMID Version="1">22566417</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2012 Jun 10;30(17):2094-101</RefSource><PMID Version="1">22564992</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Gen Intern Med. 2013 Feb;28(2):208-15</RefSource><PMID Version="1">22948932</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA Intern Med. 2013 Jan 14;173(1):54-61</RefSource><PMID Version="1">23229831</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Behav Med. 2013 Oct;46(2):237-42</RefSource><PMID Version="1">23536121</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Blood. 2014 Oct 9;124(15):2316-7</RefSource><PMID Version="1">25301330</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015122" MajorTopicYN="N">6-Mercaptopurine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044469" MajorTopicYN="N">Continental Population Groups</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="N">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055118" MajorTopicYN="N">Medication Adherence</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054198" MajorTopicYN="N">Precursor Cell Lymphoblastic Leukemia-Lymphoma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4192748</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24829202</ArticleId><ArticleId IdType="pii">blood-2014-01-552166</ArticleId><ArticleId IdType="doi">10.1182/blood-2014-01-552166</ArticleId><ArticleId IdType="pmc">PMC4192748</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li><li>Colorado</li><li>Michigan</li><li>Minnesota</li><li>Pennsylvanie</li><li>Tennessee</li></region></list><tree><noCountry><name sortKey="Ravindranath, Yaddanapudi" sort="Ravindranath, Yaddanapudi" uniqKey="Ravindranath Y" first="Yaddanapudi" last="Ravindranath">Yaddanapudi Ravindranath</name></noCountry><country name="États-Unis"><region name="Californie"><name sortKey="Bhatia, Smita" sort="Bhatia, Smita" uniqKey="Bhatia S" first="Smita" last="Bhatia">Smita Bhatia</name></region><name sortKey="Bostrom, Bruce" sort="Bostrom, Bruce" uniqKey="Bostrom B" first="Bruce" last="Bostrom">Bruce Bostrom</name><name sortKey="Casillas, Jacqueline" sort="Casillas, Jacqueline" uniqKey="Casillas J" first="Jacqueline" last="Casillas">Jacqueline Casillas</name><name sortKey="Chen, Yanjun" sort="Chen, Yanjun" uniqKey="Chen Y" first="Yanjun" last="Chen">Yanjun Chen</name><name sortKey="Crews, Kristine R" sort="Crews, Kristine R" uniqKey="Crews K" first="Kristine R" last="Crews">Kristine R. Crews</name><name sortKey="Dickens, David S" sort="Dickens, David S" uniqKey="Dickens D" first="David S" last="Dickens">David S. Dickens</name><name sortKey="Evans, William E" sort="Evans, William E" uniqKey="Evans W" first="William E" last="Evans">William E. Evans</name><name sortKey="Hageman, Lindsey" sort="Hageman, Lindsey" uniqKey="Hageman L" first="Lindsey" last="Hageman">Lindsey Hageman</name><name sortKey="Kim, Heeyoung" sort="Kim, Heeyoung" uniqKey="Kim H" first="Heeyoung" last="Kim">Heeyoung Kim</name><name sortKey="Landier, Wendy" sort="Landier, Wendy" uniqKey="Landier W" first="Wendy" last="Landier">Wendy Landier</name><name sortKey="Maloney, Kelly W" sort="Maloney, Kelly W" uniqKey="Maloney K" first="Kelly W" last="Maloney">Kelly W. Maloney</name><name sortKey="Neglia, Joseph P" sort="Neglia, Joseph P" uniqKey="Neglia J" first="Joseph P" last="Neglia">Joseph P. Neglia</name><name sortKey="Relling, Mary V" sort="Relling, Mary V" uniqKey="Relling M" first="Mary V" last="Relling">Mary V. Relling</name><name sortKey="Ritchey, A Kim" sort="Ritchey, A Kim" uniqKey="Ritchey A" first="A Kim" last="Ritchey">A Kim Ritchey</name><name sortKey="Wong, F Lennie" sort="Wong, F Lennie" uniqKey="Wong F" first="F Lennie" last="Wong">F Lennie Wong</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004158 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 004158 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:24829202
|texte= 6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:24829202" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a PittsburghV1
| This area was generated with Dilib version V0.6.38. |  |